RARITAN, N.J., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.
According to the Centers for Disease Control and Prevention (CDC), two million Americans develop hospital-acquired infections each year, and approximately 90,000 die as a result. Approximately 70 percent of these infections are resistant to at least one antibiotic. Pneumonia is the second, most-common, hospital-acquired infection in the United States and is associated with substantial morbidity and mortality.
Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by Gram-negative(1) and Gram-positive(2) bacteria. The data supporting the NDA showed doripenem was an effective treatment for hospital-acquired pneumonia. The data also demonstrated the effectiveness of doripenem against infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa and Enterobacteriaceae, including strains of these bacteria that are resistant to other therapies.
Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections and, because of increasing multi-drug resistance, treatment options are limited. In general, there are few antibiotics available or currently in development to treat the resistant infections - which can be potentially life-threatening - associated with these Gram-negative bacteria.
In clinical trials, doripenem was well-tolerated. The most common treatment-emergent adverse events seen were diarrhea, nausea, constipation, urinary tract infection and decubitus ulcer, commonly known as a bedsore. Page: 1 Related medicine news :1
. Prostate Cancer Can Be Treated By Application Of LASER Technology2
. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human3
. Venus Remedies Files 5th International Patent Application4
. Roche puts in an Application to Use Herceptin for Treatment in Her-2 positive breast cancer5
. Recd Number of Abstracts Submitted for Sci Cong on Osteoporosis6
. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke7
. Astrazenecas Investigational Cancer Therapies Revealed at ASCO8
. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli9
. Antibiotics Helps Autism10
. Antibiotics losing their power against acne11
. Antibiotic induces liver damage in children with E.COLI infections.